TRPC5 inhibitor compounds and intermediate thereof, preparation method therefor and use thereof

A compound represented by formula I-a, a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof;

• wherein
• n is 0, 1, 2, 3, or 4;
• R1 is independently —CN, halogen, —OH, C1-C4 alkyl, or C1-C4 alkyl substituted by 1, 2, 3, or 4 R1-1 groups;
• R1-1 is independently —CN, halogen, or —OH;
• L is a single bond or —CRaRb—;
• Ra is H or C1-C3 alkyl;
• Rb is H, halogen, or C1-C3 alkyl;
• R2 is
• X1 is —O—, —S—, —NH—, —O—CH2—, —S—CH2—, —NH—CH2—, —CH2—, or —CH2—CH2—;
• X2 is —O—, —S—, —NH—, —O—CH2—, —S—CH2—, —NH—CH2—, —CH2—, or —CH2—CH2—;
• R2-1 and R2-2 are independently —OR2-1-1, —SR2-1-1, or —NR2-1-2R2-1-3;
• R2-1-1 is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkyl substituted by 1, 2, 3, or 4 R2-1-1-1 groups, or C3-C6 cycloalkyl substituted by 1, 2, 3, or 4 R2-1-1-1 groups;
• R2-1-1-1 is independently —CN, F, Cl, Br, I, —OH, —NH2, —COOH, or —NO2;
• R2-1-2 and R2-1-3 are independently H or C1-C6 alkyl;
• R2-3 is H, F, Cl, Br, I, —CN, —NO2, —NH2, C1-C3 alkyl, or C1-C3 alkoxy;
• R2-4 is H, F, Cl, Br, I, —CN, —NO2, —NH2, C1-C3 alkyl, or C1-C3 alkoxy;
• R2-5 is —OR2-5-1, —SR2-5-1, or —NR2-5-2R2-5-3;
• R2-5-1 is independently H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkyl substituted by 1, 2, 3, or 4 R2-5-1-1 groups, or C3-C6 cycloalkyl substituted by 1, 2, 3, or 4 R2-5-1-1 groups;
• R2-5-1-1 is independently —CN, F, Cl, Br, I, —OH, —NH2, —COOH, or —NO2;
• R2-2 and R2-5-3 are independently H or C1-C6 alkyl;
• R2-6 is C1-C8 alkyl, C3-C6 cycloalkyl, —NR2-6-2R2-6-3, C1-C8 alkyl substituted by 1, 2, 3, or 4 R2-6-1 groups, or C3-C6 cycloalkyl substituted by 1, 2, 3, or 4 R2-6-1 groups;
• R2-6-1 is independently —CN, F, Cl, Br, I, —OH, —NH2, —COOH, or —NO2;
• R2-6-2 and R2-6-3 are independently H or C1-C6 alkyl.